TAU BIO-LOGIC’S scientific strategy is to target neurotoxic protein fragments that directly drive disease pathology and stems from the pioneering work of its founder, Daniel G. Chain, PhD, who in the 1990s, first recognized the therapeutic potential of monoclonal antibodies specifically targeting the N- or C-terminus neoepitopes which are formed at the ends of fragments generated through proteolytic cleavage of a precursor protein. The company’s lead candidate is a picomolar affinity humanized monoclonal antibody TBL-100 that targets the most noxious form of tau protein, C-terminally truncated fragment (tauC3) with an affinity that is 1000-fold greater than for full-length tau (FLT). TauC3 exists in lower abundance than FLT or N-terminally truncated tau but exerts disproportionately large pathological effects. The high affinity and specificity of the antibody are expected to translate into improved efficacy and safety compared to other tau antibodies and small molecule tau aggregation inhibitors currently in development. TAU BIO-LOGIC collaborated with LifeArc (www.lifearc.org) to generate an optimal humanized candidate for development and is partnering with additional world class organizations to gain access to cutting edge technology and manufacturing expertise.
Commitment to Innovation
Alzheimer’s disease (AD) is the most common cause of dementia and represents an enormous and growing global public health challenge. It is a uniformly fatal neurodegenerative disorder with no substantially effective treatment. Alzheimer’s Disease International estimated that as of 2013 44 million people had dementia worldwide, a figure which is expected to increase to 76 million people in 2030 and to 136 million in 2050 because of the aging of societies globally (Alzheimer’s Disease International 2013). In the United States, the prevalence of AD was estimated at 5 million people in 2015, a figure which is anticipated to increase to 7 million in 2025 and to 14 million by 2050 (Alzheimer’s Association 2015). AD is a strongly age-associated disorder with onset mainly in later life; thus, the great majority of individuals with the condition are over 65 years of age. Within the older adult population, the prevalence of AD increases dramatically from the sixth through the ninth decade; approximately one-third of individuals with AD currently are 85 years of age or older.
TAU BIO-LOGIC is now developing TBL-100 for the treatment of AD and PSP. The humanized antibody has an affinity for tauC3 of 13pM (about 100-fold higher than most marketed therapeutic antibodies have for their target) and a specificity that is 1000-fold greater than for FLT. The high affinity and specificity of the antibody are expected to translate into improved efficacy and safety compared to other tau antibodies currently in development.